Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.44 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8944853 | 0.89 | SIGMAR1 (0.44) | KDM4ETDP1ALDH1A1POLBSIGMAR1 | |
| SCHEMBL8944513 | 0.86 | SIGMAR1 (0.44) | KDM4EALDH1A1SIGMAR1KMT2A | |
| SCHEMBL2387265 | 0.81 | KDM4E (0.44) | KDM4ETDP1ALDH1A1POLBSIGMAR1 | |
| SCHEMBL8944590 | 0.75 | KDM4E (0.45) | KDM4ETDP1ALDH1A1POLBSIGMAR1 | |
| SCHEMBL8944554 | 0.75 | SIGMAR1 (0.44) | KDM4EALDH1A1SIGMAR1CYP2A13MAPT | |
| SCHEMBL8944703 | 0.75 | SIGMAR1 (0.41) | KDM4EALDH1A1SIGMAR1KMT2A | |
| SCHEMBL8944864 | 0.74 | L3MBTL1 (0.42) | KDM4EALDH1A1SIGMAR1KMT2A | |
| SCHEMBL8944769 | 0.72 | ALDH1A1 (0.47) | KDM4EALDH1A1SIGMAR1MAPTKMT2A | |
| SCHEMBL8944696 | 0.71 | NISCH (0.41) | KDM4ESIGMAR1NISCHKMT2A | |
| SCHEMBL8944610 | 0.70 | KMT2A (0.39) | KDM4EALDH1A1SIGMAR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0638568-B1 | Substituted piperazines, their process of preparation and the pharmaceutical compositions containing them | ADIR (FR) | 1996-10-09 | — | — | EP | claimed |
| US-5500426-A | ADMINISTERED TO IMPROVE GLUCOSE TOLERANCE | ADIR ET COMPAGNIE (FR) | 1996-03-19 | — | — | US | claimed |
| US-5492912-A | IMPROVES GLUCOSE TOLERANCE | ADIR ET COMPAGNIE (FR) | 1996-02-20 | — | — | US | claimed |
| EP-0638568-A1 | Substituted piperazines, their process of preparation and the pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1995-02-15 | — | — | EP | claimed |
| US-20110229571-A1 | Pharmaceutical Compositions Comprising a Selective I1 Imidazoline Receptor Agonist and an Angiotensin II Receptor Blocker | ABBOTT PRODUCTS GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| WO-2008157537-A2 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC (US) | 2008-12-24 | — | — | WO | disclosed |
| US-7309706-B2 | Method for the treatment of diseases requiring inhibition or a reduction in the activity of pH value-regulating bicarbonate transporter proteins | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-12-18 | — | — | US | disclosed |
| EP-1673107-A2 | PHARMACEUTICAL COMPOSITION COMPRISING A SELECTIVE I1 IMIDAZOLINE RECEPTOR AGONIST AND AN ANGIOTENSIN II RECEPTOR BLOCKER | Solvay Pharmaceuticals GmbH (DE) | 2006-06-28 | — | — | EP | disclosed |
| US-20050165080-A1 | Method for the treatment of diseases requiring inhibition or a reduction in the activity of pH value-regulating bicarbonate transporter proteins | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-07-28 | — | — | US | disclosed |
| US-20050143435-A1 | Pharmaceutical compositions comprising a selective I1 imidazoline receptor agonist and an angiotensin II receptor blocker | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-06-30 | — | — | US | disclosed |
| WO-2005039639-A2 | PHARMACEUTICAL COMPOSITION COMPRISING A SELECTIVE I1 IMIDAZOLINE RECEPTOR AGONIST AND AN ANGIOTENSIN II RECEPTOR BLOCKER | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-05-06 | — | — | WO | disclosed |
| EP-1517688-A2 | MEDICAMENT FOR THE TREATMENT OF DISEASES REQUIRING INHIBITION OR A REDUCTION IN THE ACTIVITY OF PH VALUE-REGULATING BICARBONATE TRANSPORTER PROTEINS | Solvay Pharmaceuticals GmbH (DE) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004000312-A2 | MEDICAMENT FOR THE TREATMENT OF DISEASES REQUIRING INHIBITION OR A REDUCTION IN THE ACTIVITY OF PH VALUE-REGULATING BICARBONATE TRANSPORTER PROTEINS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2003-12-31 | — | — | WO | disclosed |
| EP-0638568-B1 | Substituted piperazines, their process of preparation and the pharmaceutical compositions containing them | ADIR (FR) | 1996-10-09 | — | — | EP | disclosed |
| US-5500426-A | ADMINISTERED TO IMPROVE GLUCOSE TOLERANCE | ADIR ET COMPAGNIE (FR) | 1996-03-19 | — | — | US | disclosed |
| US-5492912-A | IMPROVES GLUCOSE TOLERANCE | ADIR ET COMPAGNIE (FR) | 1996-02-20 | — | — | US | disclosed |
| EP-0638568-A1 | Substituted piperazines, their process of preparation and the pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1995-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165080-A1 | Method for the treatment of diseases requiring inhibition or a reduction in the activity of pH value-regulating bicarbonate transporter proteins | CHERP, MLNR, SLC18A2 | KDM4E 3712/4885TDP1 4517/4885ALDH1A1 4398/4885 |
| US-20050143435-A1 | Pharmaceutical compositions comprising a selective I1 imidazoline receptor agonist and an angiotensin II receptor blocker | AGTR2, AGTR1, REN | KDM4E 4349/4885TDP1 3483/4885ALDH1A1 3177/4885 |
| US-20110229571-A1 | Pharmaceutical Compositions Comprising a Selective I1 Imidazoline Receptor Agonist and an Angiotensin II Receptor Blocker | AGTR2, AGTR1, REN | KDM4E 4312/4885TDP1 4171/4885ALDH1A1 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.